Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potentially best-in-class medicines for serious and rare diseases, today announced it entered into a royalty financing agreement with DRI Healthcare Acquisitions LP (DRI) and accelerated its timelines for the submission of the veligrotug BLA and the topline clinical data readouts of its VRDN-003 REVEAL trials in patients with thyroid eye dis